Direct to consumer advertising of prescription drugs

BMJ

Volumn 337, Issue 7669, 2008, Pages 526-527

  Mintzes, Barbara ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; ETANERCEPT; MOMETASONE FUROATE; ROFECOXIB; TEGASEROD; DRUG;

ALLERGY; ANGINA PECTORIS; CANADA; CONSTIPATION; DRUG COST; DRUG MARKETING; EDITORIAL; HEART INFARCTION; HUMAN; IRRITABLE COLON; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; RHEUMATOID ARTHRITIS; STROKE; TELEVISION; UNITED STATES; ADVERTIZING; NOTE;

ADVERTISING AS TOPIC; CANADA; HUMANS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG;

EID: 51649118131     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a985     Document Type: Editorial

References (11)

1. Law M, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada. BMJ 2008;337:a1055.
2. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007;(4):CD003960.
3. US Food and Drug Administration. Center for Drug Evaluation and Research. FDA Public Health Advisory. Tegaserod maleate (marketed as Zelnorm). 2007. www.fda.gov/cder/drug/advisory/tegaserod.htm.
4. Canadian Institute for Health Information. Drug expenditure in Canada 1985 to 2007. 2008. http://secure.cihi.ca/cihiweb/products/ Drug_Expenditure_in_Canada_1985_2007_e.pdf.
5. Morgan S, Bassett KL, Mintzes B. Outcomes based coverage in British Columbia. Health Affairs 2004;23:269-76.
6. Heinrich J. Drug safety: most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R. Washington: US General Accounting Office, 2001.
7. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-91.
8. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med 2007;5:6-13.
9. Health Canada. Important safety update. Diarrhea and ischemic colitis in patients using Zelnorm (tegaserod hydrogen maleate). (Dear health professional letter.) Dorval (QC): Novartis Pharmaceuticals, 2004. www.nlpb.ca/Documents/Advisories/Health_Canada_Advisory_Archive_2004-2006.pdf.
10. US Food and Drug Administration. FDA updates Zelnorm labeling with new risk information. FDA talk paper. TO4-10. 2004. www.fda.gov/bbs/topics/ ANSWERS/2004/ANS01285.html.
11. Topol EJ. Failing the public health - rofecoxib, Merck and the FDA. N Engl J Med 2004;351:1707-9.